Marksans Pharma Files BRSR for FY 2025-26

Marksans Pharma Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per SEBI regulations. The report details the company's corporate identity, business activities, operations, and employee data. The company's primary business activity is the research, manufacturing, and sales of pharmaceutical formulations, accounting for 100% of its turnover. Marksans Pharma operates with a significant international presence, serving over 50 countries and deriving 100% of its turnover from exports. The report also provides employee statistics, highlighting a total of 1231 employees and 1004 workers, with a notable female representation of 14.54% among employees and 11.75% among workers.